Claims for Patent: 6,670,460

Summary for Patent: 6,670,460

Title:	Method of detection of alterations in MSH5
Abstract:	We have now discovered that mammals, have a DNA gene analogous to that existing in bacteria. MSH5 defects or alterations in this mismatch repair pathway in a mammal, such as a human can be diagnostic of a predisposition to cancer, and prognostic for a particular cancer. We have discovered and sequenced MSH5 in this in a number of mammals, including humans. This gene, can be used in assays, to express gene product, for drug screens, and therapeutically.
Inventor(s):	Kolodner; Richard (San Diego, CA), Winand; Nena (Freeville, NY)
Assignee:	Dana-Farber Cancer Institute, Inc. (Boston, MA)
Application Number:	09/470,276
Patent Claims:	1. An isolated and purified nucleotide segment, wherein said nucleotide segment is a fragment of at least 25 contiguous nucleotides between nucleotides 235-1908 of SEQ ID NO: 1, and wherein said nucleotide segment is mRNA or cDNA. 2. An isolated and purified nucleotide segment having the sequence as set forth in SEQ ID NO.:1. 3. An isolated and purified nucleotide segment having the sequence as set forth in SEQ ID NO:1, wherein said segment is no more than 6000 nucleotides. 4. The isolated and purified nucleic acid segment of claim 3, wherein said nucleotide segment consists of SEQ ID NO:1. 5. An isolated nucleotide sequence segment consisting of at least 25 contiguous nucleotides from at least one exon from SEQ ID NO: 1, wherein the sequence is selected from the group consisting of exons 1-24 wherein exon 1 starts at position 235 and continues continuously for 221 basepairs, exon 2 is the next 160 basepairs, exon 3 is the next 124 basepairs, exon 4 is the next 81 basepairs, exon 5 is the next 63 basepairs, exon 6 is the next 122 basepairs, exon 7 is the next 110 basepairs, exon 8 is the next 36 basepairs, exon 9 is the next 83 basepairs, exon 10 is the next 46 basepairs, exon 11 is the next 139 basepairs, exon 12 is the next 63 basepairs, exon 13 is the next 129 basepairs, exon 14 is the next 73 basepairs, exon 15 is the next 110 basepairs, exon 16 is the next 81 basepairs, exon 17 is the next 88 basepairs, exon 18 is the next 190 basepairs, exon 19 is the next 127 basepairs, exon 20 is the next 150 basepairs, exon 21 is the next 75 basepairs, exon 22 is the next 144 basepairs, exon 23 is the next 138 basepairs and exon 24 is the next 74 basepairs. 6. The isolated and purified nucleic acid of claim 5, further comprising a radioactive label or a fluorescent tag. 7. The isolated nucleotide segment of claim 5, wherein said fragment are selected from nucleotides 235-1908 of SEQ ID NO:1. 8. A kit for determining an alteration in a mammalian MSH5 gene by DNA amplification comprising: a set of DNA oligonucleotide primers in a vial, the set allowing synthesis of a DNA encoding the DNA mismatch repair gene, wherein said primers are selected from the isolated nucleotide segments of claim 1 or 5. 9. A vector containing the DNA of claim 1 or 3 or 5. 10. The vector of claim 9, wherein said vector is a retroviral vector. 11. A host transformed with the vector of claim 9. 12. An isolated nucleic acid segment consisting of a nucleotide sequence selected from the group consisting of SEQ ID Nos: 3-53. 13. A kit for determining an alteration in a mammalian MSH5 gene by DNA amplification comprising: a set of DNA oligonucleotides primers in a vial, said set allowing synthesis of a DNA ending the DNA mismatch repair gene, wherein said primers are selected from the group consisting of SEQ ID NOS:3-50. 14. The isolated and purified nucleotide segment of claim 3, wherein the nucleotide segment is the coding region of SEQ ID NO:1. 15. An isolated and purified nucleotide segment, wherein said nucleotide segment is a fragment of at least 25 contiguous nucleotides between nucleotides 235-1908 of SEQ ID NO: 1, and wherein said nucleotide segment is mRNA or cDNA. 16. An isolated and purified nucleotide segment encoding the amino acid sequence of SEQ ID NO:2, wherein said nucleotide segment is mRNA or cDNA. 17. An isolated and purified nucleotide sequence segment consisting of: (a) at least one exon from SEQ ID NO:1 wherein starting at position 235 and continuing continuously, exon 1 is 221 basepairs, exon 2 is the next 160 basepairs, exon 3 is the next 124 basepairs, exon 4 is the next 81 basepairs, exon 5 is the next 63 basepairs, exon 6 is the next 122 basepairs, exon 7 is the next 110 basepairs, exon 8 is the next 36 basepairs, exon 9 is the next 83 basepairs, exon 10 is the next 46 basepairs, exon 11 is the next 139 basepairs, exon 12 is the next 63 basepairs, exon 13 is the next 129 basepairs, exon 14 is the next 73 basepairs, exon 15 is the next 110 basepairs, exon 16 is the next 81 basepairs, exon 17 is the next 88 basepairs, exon 18 is the next 190 basepairs, exon 19 is the next 127 basepairs, exon 20 is the next 150 basepairs, exon 21 is the next 75 basepairs, exon 22 is the next 144 basepairs, exon 23 is the next 138 basepairs, exon 24 is the next 74 basepairs, and exon 25 is the next 254 basepairs; (b) at least one intron sequence, wherein said intron sequence is selected from the group of hMSH5 introns consisting of SEQ. ID NOS:55-85.

Details for Patent 6,670,460

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-07-03
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-07-03
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-07-03